mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation

Demongeot, Jacques; Fougère, Cécile

doi:10.3390/vaccines11010040

Cited by 3 publications

(2 citation statements)

References 187 publications

(256 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, for the USA and India, a minimum of the ID variable was impossible to individualize inside the endemic background noise. The future efforts in the direction of this research are vital for a future pandemic or emerging infectious disease preparation, because we believe that the research presented in this article could be relevant for new infectious case forecasting in order to deploy proper intervention and resources (as vaccination policies [ 48 ]) to fight the epidemic spread and, in a way, guide policy-making for public health.…”

Section: Discussionmentioning

confidence: 99%

Forecasting the Endemic/Epidemic Transition in COVID-19 in Some Countries: Influence of the Vaccination

Waku,

Oshinubi,

Adam

et al. 2023

Diseases

Self Cite

View full text Add to dashboard Cite

Objective: The objective of this article is to develop a robust method for forecasting the transition from endemic to epidemic phases in contagious diseases using COVID-19 as a case study. Methods: Seven indicators are proposed for detecting the endemic/epidemic transition: variation coefficient, entropy, dominant/subdominant spectral ratio, skewness, kurtosis, dispersion index and normality index. Then, principal component analysis (PCA) offers a score built from the seven proposed indicators as the first PCA component, and its forecasting performance is estimated from its ability to predict the entrance in the epidemic exponential growth phase. Results: This score is applied to the retro-prediction of endemic/epidemic transitions of COVID-19 outbreak in seven various countries for which the first PCA component has a good predicting power. Conclusion: This research offers a valuable tool for early epidemic detection, aiding in effective public health responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Forecasting the Endemic/Epidemic Transition in COVID-19 in Some Countries: Influence of the Vaccination

Waku,

Oshinubi,

Adam

et al. 2023

Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Following intramuscular administration, lipid nanoparticle‐packaged mRNA enters host cells via endocytosis and is translated into target proteins (as seen in Pfizer‐BioNTech and Moderna vaccines) by ribosomes 12,13 . These proteins are then processed and presented as antigens on the cell surface by major histocompatibility complex (MHC) class I and II molecules, activating the T‐cell receptor (TCR) and thereby stimulating the adaptive immune system 14,15 .…”

Section: Introductionmentioning

confidence: 99%

In vitro mRNA‐S maternal vaccination induced altered immune regulation at the maternal‐fetal interface

Kammala,

Tatiparthy,

Thomas

et al. 2024

American J Rep Immunol

View full text Add to dashboard Cite

BackgroundMaternal‐fetal immunology is intricate, and the effects of mRNA‐S maternal vaccination on immune regulation at the maternal‐fetal interface require further investigation. Our study endeavors to elucidate these immunological changes, enhancing our comprehension of maternal and fetal health outcomes. By analyzing immune profiles and cytokine responses, we aim to provide valuable insights into the impact of mRNA‐S vaccination on the delicate balance of immune regulation during pregnancy, addressing critical questions in the field of reproductive pharmacology.ObjectivesThis investigation sought to examine the prospective influence of mRNA‐S‐based vaccines and extracellular vesicles (EVs) containing the Spike (S) protein at the maternal‐fetal interface. Our primary emphasis was on evaluating their effects on maternal decidua cells and fetal chorion trophoblast cells (hFM‐CTCs).MethodsWe validated the generation of EVs containing the S protein from small human airway epithelial cell lines (HSAECs) following mRNA‐S vaccine exposure. We assessed the expression of angiotensin‐converting enzyme 2 (ACE2) gene and protein in fetal membranes and the placenta, with specific attention to decidual cells and fetal membrane chorion cells. To assess cellular functionality, these cells were exposed to both recombinant S protein and EVs loaded with S proteins (eSPs).ResultsOur findings revealed that cells and EVs subjected to mRNA‐S‐based vaccination exhibited altered protein expression levels of S proteins. At the feto‐maternal interface, both placental and fetal membrane tissues demonstrated similar ACE‐2 expression levels. Among individual cellular layers, syncytiotrophoblast cells in the placenta and chorion cells in the fetal membrane exhibited elevated ACE‐2 expression. Notably, EVs derived from HSAECs activated the MAPK pathway in decidual cells. Additionally, decidual cells displayed a substantial increase in gene expression of chemokines like CXCL‐10 and CXCL‐11, as well as proinflammatory cytokines such as IL‐6 in response to eSPs. However, the levels of Ccl‐2 and IL‐1β remained unchanged in decidual cells under the same conditions. Conversely, hFM‐CTCs demonstrated significant alterations in the proinflammatory cytokines and chemokines with respect to eSPs.ConclusionIn conclusion, our study indicates that mRNA‐S‐based maternal vaccination during pregnancy may influence the maternal‐fetal interface's COVID‐19 interaction and immune regulation. Further investigation is warranted to assess safety and implications.

show abstract

The Platform Technology Approach to mRNA Product Development and Regulation

Skerritt,

Tucek-Szabo,

Sutton

et al. 2024

Vaccines

View full text Add to dashboard Cite

mRNA-lipid nanoparticle (LNP) medicinal products can be considered a platform technology because the development process is similar for different diseases and conditions, with similar noncoding mRNA sequences and lipid nanoparticles and essentially unchanged manufacturing and analytical methods often utilised for different products. It is critical not to lose the momentum built using the platform approach during the development, regulatory approval and rollout of vaccines for SARS-CoV-2 and its variants. This review proposes a set of modifications to existing regulatory requirements for mRNA products, based on a platform perspective for quality, manufacturing, preclinical, and clinical data. For the first time, we address development and potential regulatory requirements when the mRNA sequences and LNP composition vary in different products as well. In addition, we propose considerations for self-amplifying mRNA, individualised oncology mRNA products, and mRNA therapeutics. Providing a predictable development pathway for academic and commercial groups so that they can know in detail what product characterisation and data are required to develop a dossier for regulatory submission has many potential benefits. These include: reduced development and regulatory costs; faster consumer/patient access and more agile development of products in the face of pandemics; and for rare diseases where alternatives may not exist or to increase survival and the quality of life in cancer patients. Therefore, achieving consensus around platform approaches is both urgent and important. This approach with mRNA can be a template for similar platform frameworks for other therapeutics and vaccines to enable more efficient development and regulatory review.

show abstract

mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation

Cited by 3 publications

References 187 publications

Forecasting the Endemic/Epidemic Transition in COVID-19 in Some Countries: Influence of the Vaccination

Forecasting the Endemic/Epidemic Transition in COVID-19 in Some Countries: Influence of the Vaccination

In vitro mRNA‐S maternal vaccination induced altered immune regulation at the maternal‐fetal interface

The Platform Technology Approach to mRNA Product Development and Regulation

Contact Info

Product

Resources

About